Find, compare & contact
Liraglutidum (Liraglutide)
API Manufacturers & Suppliers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Distributor
Produced in:
Established in: 1987
MOQ: 1 kg
Employees: 50+
ISO 9001:2015 & SGS audited supplier
One-stop CDMO Solutions for APl and Key intermediates
Specialized in APIs & Pharmaceutical Intermediates for 37 years
+ 0
All certificates
Distributor
Produced in:
Established in: 1994
MOQ: -
Employees: 50+
26+ years of distribution expertise with regulatory excellence
16 worldwide locations supplying high quality ingredients
All our manufacturer partners are cGMP complaint
+ 0
All certificates
Distributor
Produced in:
Established in: 2005
MOQ: -
Employees: 200+
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
+ 0
All certificates
Produced in:
Established in: 2017
MOQ: -
Employees: 200+
Manufacturing facility approved by FDA and GMP certified
Obtained CNAS laboratory accreditation certificate
Subsidiary of the US listed group Amphastar Pharmaceuticals
+ 0
All certificates
Producer
Produced in:
Established in: 2013
MOQ: 1 kg
Employees: 25+
ISO9001 certified
Drug R&D center (in Hangzhou)
From lab scale (mg/g) to commercial scale (kgs/tons)
+ 0
All certificates
Producer
Produced in:
Established in: 2005
MOQ: 1 kg
Employees: 85
Strict quality control
15 years of experience in API production
Provide OEM & ODM service
+ 0
All certificates
Producer
Produced in:
Established in: 2019
MOQ: 1 g
Employees: 10+
Focused on pharmaceutical industry
Reasonable price for the customers
Full service from R&D stage to commercial stage
+ 0
All certificates
Producer
Produced in:
Established in: 2011
MOQ: 1 g
Employees: 10+
Fast Response and Good Communication
Willingness To Start From Small
Flexible Payment Terms
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
Produced in:
Established in: 1984
MOQ: -
Employees: 21,650
Diverse portfolio of 180+APIs
1754+ DMF across global markets
1100+ patents filed, and more than 70 own patents granted
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Liraglutide API 204656-20-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Liraglutide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Liraglutide
- Synonyms:
- Liraglutida , Liraglutide recombinant , Liraglutidum
- Cas Number:
- 204656-20-2
- DrugBank number:
- DB06655
- Unique Ingredient Identifier:
- 839I73S42A
About Liraglutide
So, what does it do? Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist1. Liraglutide is 97% homologous to native human GLP-1 by substituting arginine for lysine at position 341. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor1. Liraglutide was granted FDA approval on Januray 25, 20104.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements
Liraglutide is a type of GLP1 agonists
GLP-1 agonists, short for glucagon-like peptide-1 agonists, are a subcategory of pharmaceutical APIs (active pharmaceutical ingredients) commonly used in the treatment of type 2 diabetes mellitus. These medications mimic the actions of GLP-1, a naturally occurring hormone in the body that helps regulate blood sugar levels.
GLP-1 agonists work by binding to GLP-1 receptors in the pancreas, promoting insulin secretion and inhibiting glucagon release. This mechanism of action leads to improved glucose control, reduced fasting and postprandial blood glucose levels, and decreased hemoglobin A1c levels.
One of the key advantages of GLP-1 agonists is their ability to promote weight loss in patients with type 2 diabetes. These medications slow down gastric emptying, increase satiety, and reduce food intake, resulting in modest but significant weight reduction.
Additionally, GLP-1 agonists have shown cardiovascular benefits, including a reduction in the risk of major adverse cardiovascular events, such as heart attack and stroke. They also exhibit a lower risk of hypoglycemia compared to some other antidiabetic medications.
Some commonly prescribed GLP-1 agonists include exenatide, liraglutide, dulaglutide, and semaglutide. These APIs are typically administered via subcutaneous injection, either once or twice daily, or in some cases, as weekly formulations.
In conclusion, GLP-1 agonists are a valuable class of pharmaceutical APIs used in the management of type 2 diabetes. Their mechanism of action, which includes glucose control, weight loss promotion, and cardiovascular benefits, makes them a favorable choice for patients seeking effective and safe antidiabetic therapy.
Liraglutide (GLP1 agonists), classified under Anti-diabetics
Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.
Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.
Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.
These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.
It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.
In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.
Liraglutide manufacturers | traders | suppliers
We have 13 companies offering Liraglutide produced in 5 different countries.
Get in contact with the supplier of your choice:
- Sinoway industrial Co.,Ltd from China, product country of origin China
- Rochem International, Inc. from United States, product country of origin United States
- LGM Pharma from United States, product country of origin World
- Nanjing Hanxin Pharmaceutical Technology Co.,Ltd. from China, product country of origin China
- Senova Technology Co., Ltd. from China, product country of origin China
- Xi'an Tian Guangyuan Biotech Co.,Ltd from China, product country of origin China
- Apino Pharma Co., Ltd. from China, product country of origin China
- Shandong Octagon Chemicals Limited from China, product country of origin China
- ALP PHARM from China, product country of origin China
- Hybio Pharmaceutical from China, product country of origin China
- Dr. Reddy's from India, product country of origin India
- Hainan Shuangcheng from China, product country of origin China
- AMBIOPHARM from United States, product country of origin Unknown
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.